Independent and joint associations of skeletal muscle mass and physical performance with all-cause mortality among older adults: a 12-year prospective cohort study

Chia-Ing Li1,2, Chiu-Shong Liu1,2,3, Chih-Hsueh Lin1,3, Shing-Yu Yang4, Tsai-Chung Li4,5* and Cheng-Chieh Lin1,2,3*

Abstract

Background: Decreased skeletal muscle mass and low physical performance are independently associated with increased mortality in elderly individuals. However, little is known about the effects of skeletal muscle mass combined with physical performance on the prediction of mortality risk among community-dwelling older adults. This study aimed to determine the combined effects of skeletal muscle mass and physical performance on total mortality.

Methods: A community-based prospective cohort study was conducted among 641 participants aged 65 and older in 2009. The height-adjusted skeletal muscle index (hSMI) and the weight-adjusted SMI (wSMI) were determined by dual-energy X-ray absorptiometry examination. Physical performance tests measured at baseline included gait speed (GS), timed up-and-go (TUG) test, timed chair stand (TCS), weight-adjusted leg press (WaLP), and handgrip strength (HS). Cox proportional hazards regression models were applied to determine the adjusted hazard ratios (HRs) of mortality with 95% confidence intervals (95% CIs) for baseline skeletal muscle mass, physical performance, and traditional risk factors.

Results: During the follow-up of 12 years, 198 (30.89%) participants died. Low hSMI, low GS, high TUG, high TCS, low WaLP, and low HS were associated with high risks of mortality after the adjustment for confounders. The results of receiver operating characteristic (ROC) curve analyses revealed the values of ROC for models with additional consideration for TUG or all indicators significantly improved the discriminatory ability of mortality compared with the model with traditional factors (all \( P < 0.05 \)). Elders with low hSMI and low GS (HRs = 4.33, 95% CI: 2.76–6.78), high TUG (4.11, 2.60–6.48), high TCS (2.97, 1.92–4.59), low WaLP (3.19, 2.13–4.79), and low HS (4.08, 2.70–6.17) were associated with high risks of mortality compared with those with high hSMI and their corresponding counterparts.

Conclusion: The hSMI and physical performance are significantly associated with increased risks of all-cause mortality. The combined use of hSMI and physical performance can provide improved risk stratification, which may be
and physical performance [30–32]. Thus, several investigators became interested in whether skeletal muscle mass index and physical performance are independent predictors of mortality when both measures are considered [26, 28, 29]. These studies further indicated that physical performance (such as muscle strength, timed up-and-go (TUG), etc.) is a more important predictor than SMI [26, 28, 29]. However, they did not comprehensively consider the various domains of physical performance indicators. Thus, whether or to what extent SMI and physical performance are independently or jointly associated with all-cause mortality in elderly individuals remains unclear. Therefore, more evidence is required to explore the associations between SMI and physical performance with mortality.

We searched literature thoroughly regarding the effects of skeletal muscle mass and physical performance on mortality in older or elderly individuals and found several related studies [10–29, 33–35]. Among these studies, several explored the individual effect of skeletal muscle mass [10–15, 33, 34], others examined the individual effect of physical performance [16–23, 35]. Although several studies investigated the effect of both simultaneously [24–29], with research being conducted in Finland [24], Australia [27], USA [25, 26, 29], and Korea [28], they reported independent effects of measures for skeletal muscle mass or physical performance by comparing their discriminatory ability on predicting mortality [24, 25, 27–29] except one study reporting joint effect of low muscle mass and low muscle strength [26]. However, the definition of sarcopenia proposed by the European Working Group on Sarcopenia in Older People (EWGSOP) or Asian Working Group for Sarcopenia (AWGS) is a type of joint effect of skeletal muscle mass and physical performance. In addition, these studies did not comprehensively consider various domains of physical performance indicators but focused on one or two domains of physical performance, such as gait speed (GS) only [25], leg muscle strength only [26], leg muscle and grip strength [28, 29], and grip strength and TUG [27]. New scientific evidence regarding joint effect of muscle mass and physical performance must be added in this line of research question among older adults. The current study can provide information about the joint effects of skeletal muscle mass and multiple physical performance measures in predicting all-cause mortality.

Method

Study design and study subjects
We conducted a community-based prospective cohort study among all individuals aged 65 and over in Taichung City, Taiwan in 2009. A total of 3,997 elderly residents of the North District of Taichung City were recruited in 2009. All individuals were invited to participate in the study by letter, phone, and home visit. Exactly 2,750 subjects were considered eligible after assessment, and 1,347 eligible subjects accepted our invitation to participate with an overall response rate of 49.0%. After the exclusion of participants without complete data for baseline characteristics, skeletal muscle mass, and physical performance, 641 participants were included in the final analysis (Supplement Figure S1). This present study was approved by the Ethical Review Board of China Medical University Hospital (DMR 97-IRB-055 & CMUH108-REC2-161). Written informed consent was obtained from...
all the study participants. All methods were performed in accordance with the relevant guidelines and regulations.

**Measurements**

*Sociodemographic factors, lifestyle behaviors, and disease history*

All subjects underwent a face-to-face interview with a standardized questionnaire to collect baseline characteristics consisting of socio-demographic characteristics, educational attainment level, marital status, smoking habits, habitual ethanol intake, regular exercise, personal history of hypertension, presence of diabetes, heart disease, stroke, and cancer. Persons who reported to have the characteristics of smoking, alcohol drinking, regular exercise and history of chronic diseases were placed into groups based on the specific characteristic. Those in the non-regular exercise group didn’t exercise regularly during the past month, whereas those in regular exercise group exercised regularly at least 2 times per week for 20 min during the past month. Among these participants, 146 frail or prefrail persons joined a randomized control trial, receiving home-based exercise instruction or supervised exercise program [36]. Participants receiving supervised exercise undertook a 3-month exercise training program under the supervision of a physical therapist. The participants undertook 3 exercise sessions per week, with a duration of 1.5 h per session, including 10-min warm-up and stretching activities, as well as 30-min aerobic exercise setting at between 70 and 85% of the predicted maximum heart rate, and resistance training (including strengthening of the elbow flexors utilizing dumbbells, hand grip muscles against grip strength trainers with different resistances, and lower limb muscles with a leg press machine). The participants receiving home-based exercise instruction attended a 15-min session of home-based exercise instructions. They were asked to exercise at least 3 times per week at home. Ten-page illustrated handouts describing calisthenics and resistance exercise for the upper and lower limbs were given.

**Mini-mental State Examination (MMSE)**

The MMSE was developed by Folstein M.F. and Folstein S.E. [37]. This questionnaire is designed for the graded evaluation of patients with cognitive impairment and now has become a widely used test to screen for cognitive disorders in epidemiological studies and follow-up cognitive changes in clinical trials. The MMSE contains items about time and place orientation, registration, attention and calculation, recall, and language and constructional abilities. The total score ranges between 0–30, and the cut-point score is variant with different educational levels. Cognitive impairment was considered if the total score of MMSE was less than 24, 21, and 16, with educational level of the participant more than 9 years, more than 6 years, and none, respectively [38].

**Laboratory examination**

Blood was drawn with minimal trauma from an antecubital vein in the morning after a 12 h overnight fasting and was sent for analysis within 4 h after blood collection. Blood tests, including fasting plasma glucose, total cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, triglyceride, and creatinine, were analyzed by a biochemical autoanalyzer (Beckman Coulter, Lx-20, USA) at the Clinical Laboratory Department of China Medical University Hospital. The Chronic Kidney Disease Epidemiology Collaboration equation was used to calculate the estimated glomerular filtration rate [39].

**SMI**

We performed dual-energy X-ray absorptiometry (DXA) (Lunar DPX, General Electric, Madison, WI, USA) to determine the body composition of the subjects. The lean soft tissue mass and fat mass in the arms, legs, trunk, and entire body were determined using a DXA analysis software (Lunar enCORE; General Electric). The equipment was calibrated using a standardized employed each day. DXA is recommended by The European Working Group on Sarcopenia in Older People as the preferred alternative method to measure skeletal muscle mass for research and clinical use [2] because computer tomography and magnetic resonance imaging have the disadvantages of radiation exposure and/or high costs, which limit their use in routine clinical practice.

The height-adjusted SMI (hSMI) was derived by dividing the appendicular muscle mass (kg) by the square of height (m²), whereas the weight-adjusted SMI (wSMI) was calculated by dividing the appendicular muscle mass (kg) by weight (kg) [5].

**Physical performance**

Physical performance included measures of walking speed, TUG test, timed chair stands (TCS), weight-adjusted leg press (waLP), and handgrip strength (HS). The participants underwent all physical performance tests under the instructions of a physical therapists. For the walking test, the participants were asked to walk 5 m at their usual speed. The walking speed was calculated as 5 m divided by the recorded time. The TUG test required the participant to stand up from a sitting position, walk 3 m from that position, walk back to the chair, and sit down as immediately as possible, and the time elapsed was recorded [40]. The participants in the TCS test were asked to fold their arms across their chest, to
sitting firmly in a chair, and to stand up and sit down thrice, and the time elapsed was recorded [41]. The participants were prohibited from using their hands for support during the test, and the test was repeated thrice. The shortest time elapsed was used for analysis. For wALP, submaximal leg press strength (a maximum of 10–15 repetitions) was measured by a leg press machine (AURA G3-S70, Matrix Fitness System, USA). Then, one-repetition maximum leg press strength was calculated by the Brzycki formula [42]. wALP was calculated by dividing the corresponding test results by the weight of the participant. A dynamometer (TTM Dynamometer, Tsutumi, Tokyo, Japan) was used to evaluate isometric HS in kg. Each hand was repeatedly measured thrice, and each hand’s average HS was calculated. The maximum average HS value of the left or right hand was defined as the participant’s HS.

**Outcome ascertainment**

The primary outcome measure was all-cause death status, which was determined through record linkage with the cause of death data in the Health and Welfare Data Science Center database. By linking National Registry of Death dataset, we obtained information on an individual’s date of death. The time of follow-up began with recruitment (index date) and ended with death or the end of follow-up (August 2021).

**Statistical analysis**

In descriptive analysis, the baseline variables were shown as frequency (proportion) and assessed by the Chi-square tests for categorical variables and as means ± standard deviation (SD) and assessed by the t test for continuous variables. Unadjusted and adjusted Cox proportional hazards regression models were used to calculate hazard ratio (HR) and 95% confidence interval (CI) for mortality status; the nonparametric method was used to test the differences in the AUROCs among indexes of skeletal muscle mass and physical performance [43]. All analyses were performed with SAS version 9.4 (SAS, Cary, NC). All p-values were two-tailed, and a p-value < 0.05 was considered statistically significant.

**Results**

During the median 12-year follow-up (interquartile range, 10.3–11.8 years), 198 (30.9%) elders died (of whom 135 (68.2%) from men). The mortality rate per 1000 person-years was 39.13 for men and 19.13 for women. The distributions of baseline characteristics based on the mortality status are presented as frequency (proportion) or mean (SD) in Table 1. These results indicated that elders who died compared with those who did not, had higher prevalence of hypertension, diabetes mellitus, heart disease, stroke, cancer, and cognitive impairment, higher mean values of TUG and TCS, and lower mean values of GS and wALP.

Next, the bivariate associations between all-cause mortality and measures of skeletal muscle index and physical performance were assessed by the Kaplan–Meier survival curves for all-cause mortality based on quartiles of hSMI, GS, TUG, TCS, wALP, and HS. The discriminatory ability was assessed by the AUROCs of baseline characteristics, hSMI, and each physical performance measure to correctly classify the elders’ mortality status; the nonparametric method was used to test the differences in the AUROCs among indexes of skeletal muscle mass and physical performance [43]. All analyses were performed with SAS version 9.4 (SAS, Cary, NC). All p-values were two-tailed, and a p-value < 0.05 was considered statistically significant.

Then the discriminatory ability was assessed by the AUROCs of baseline characteristics, hSMI, and each physical performance measure to correctly classify the elders’ mortality status; the nonparametric method was used to test the differences in the AUROCs among indexes of skeletal muscle mass and physical performance [43]. All analyses were performed with SAS version 9.4 (SAS, Cary, NC). All p-values were two-tailed, and a p-value < 0.05 was considered statistically significant.
Variables No (N=443) Yes (N=198) 

| Socio-demographic factors | Death N (%) | P value |
|---------------------------|-------------|---------|
| Men                       | 215 (48.53) | 135 (68.18) | < 0.001 |
| Age (years)               |             | < 0.001 |
| 65–74                     | 317 (71.56) | 77 (38.89) |
| 75–84                     | 122 (27.54) | 97 (48.99) |
| > 85                      | 4 (0.90)    | 24 (12.12) |
| Education                 |             | 0.35 |
| No education              | 46 (10.38)  | 14 (7.07)  |
| Primary education         | 118 (26.64) | 59 (29.8)  |
| Secondary or tertiary     | 279 (62.98) | 125 (63.13) |
| Married                   | 332 (74.94) | 145 (73.23) | 0.72 |
| Lifestyle behaviors        |             |         |
| Smoking                   | 39 (8.80)   | 22 (11.11) | 0.44 |
| Alcohol drinking          | 63 (14.22)  | 31 (15.66) | 0.72 |
| Regular exercise          | 354 (79.91) | 147 (74.24) | 0.13 |
| Disease history           |             |         |
| Hypertension              | 200 (45.15) | 117 (59.09) | 0.002 |
| Diabetes Mellitus         | 49 (11.06)  | 42 (21.21) | 0.001 |
| Heart disease             | 110 (24.83) | 79 (39.90) | < 0.001 |
| Stroke                    | 11 (2.48)   | 22 (11.11) | < 0.001 |
| Cancer                    | 18 (4.06)   | 17 (8.59)  | 0.03 |
| Cognitive impairment      |             |         |
| Fasting plasma glucose    | 106.75 ± 22.07 | 114.21 ± 31.3    | 0.003 |
| Triglyceride (mg/dL)      | 115.65 ± 63.84 | 117.09 ± 72.81   | 0.81 |
| High-density lipoprotein  | 47.00 ± 13.38 | 45.03 ± 15.90    | 0.13 |
| Low-density lipoprotein   | 116.99 ± 31.38 | 109.65 ± 30.04  | 0.006 |
| eGFR (mL/min per 1.73 m²) | 77.11 ± 14.96 | 68.66 ± 18.79    | < 0.001 |
| Height-adjusted SMI (kg/m²) | 6.96 ± 1.02 | 6.89 ± 1.04 | 0.39 |
| Weight-adjusted SMI (%)   | 28.72 ± 4.17 | 29.07 ± 4.48 | 0.35 |
| Physical performance      |             |         |
| Gait speed (m/s)          | 0.88 ± 0.18  | 0.73 ± 0.23    | < 0.001 |
| Timed up-and-go test (sec)| 7.21 ± 2.04  | 9.31 ± 4.46    | < 0.001 |
| Timed chair stand (sec)   | 5.03 ± 1.48  | 6.25 ± 2.96    | < 0.001 |
| Weight-adjusted leg press (%)| 96.87 ± 36.52 | 78.51 ± 36.95 | < 0.001 |
| Handgrip strength (kg)    | 28.00 ± 7.95 | 27.17 ± 7.73   | 0.22 |

Mean ± standard deviation for continuous variables; numbers (percentage) for categorical variables

eGFR Estimated glomerular filtration rate, SMI Skeletal muscle mass

for models with additional consideration for TUG and all skeletal muscle index and physical performance variables were significantly higher than that for model with baseline characteristics (both \( p < 0.01 \)).

The interactions between skeletal muscle index and physical performance were assessed and none of these interactions are significant (all \( p > 0.05 \)). Thus, the joint effects of hSMI with GS, TUG, TCS, or HS on death risks were displayed (Fig. 2). The results showed that the lowest hSMI quartile combined with the lowest GS quartile, highest TUS quartile, highest TCS quartile, lowest WaLP, or lowest HS were associated with three- to fourfold higher mortality (HRs=4.33, 95% CI: 2.76–6.78; 4.11, 2.60–6.48, 2.97, 1.92–4.59; 3.19, 2.13–4.79; 4.08, 2.70–6.17, respectively).

**Discussion**

In this 12-year follow-up prospective study, hSMI and physical performance measures of GS, TUG, TCS, WaLP, and HS exhibited independent association with long-term mortality among older adults. A positive linear association was also observed with the numbers of risk factors. Among the measures of skeletal muscle index and physical performance, the additional consideration of TUG or all measures had significantly improved the discriminatory ability for all-cause mortality.

A previous meta-analysis revealed an inverse association between hSMI and mortality in older adults, and the study’s results showed a smaller magnitude of difference in muscle mass between older adults who died and survived [44]. Although the present study used different perspective to examine the association between hSMI and mortality, we observed that older persons with higher levels of hSMI were associated with a lower risk of 12-year mortality. Our study’s findings were consistent with those reported in a Korean elderly cohort with a 5-year follow-up period, indicating that decrease in appendicular skeletal mass was associated with mortality in both sexes [28]. In addition, two observational cohort studies in Asia conducted in special populations reported that hSMI was associated with mortality in women among nonagenarians and centenarians in China [10] or patients with type 2 diabetes in Japan [45]. On the contrary, in a study conducted in Japanese persons aged between 40–79 years old of the Longitudinal Study of Aging, Japan, a higher level of hSMI was not associated with the composite outcome measure of mortality or disability after multivariate adjustment [13]. The possible explanation why muscle mass cannot be used to predict mortality or disability in this Japan study was that the study subjects included adults and elderly (age range of 40–79 years), and adults generally face a lower risk of mortality than elders and were less likely to suffer lean...
Table 2: Hazards ratios of all-cause mortality for measures of skeletal muscle index and physical performance

| Variables                      | N     | Deaths | Person- years | Incidence rate | HR (95% CI)          |
|--------------------------------|-------|--------|---------------|----------------|----------------------|
|                                |       |        |               |                |                      |
|                                |       |        |               |                | Crude               |
|                                |       |        |               |                | Multivariate-adjusted\(^1\) |
|                                |       |        |               |                | Multivariate-adjusted\(^2\) |
| **Height-adjusted SMI (kg/m\(^2\))** |       |        |               |                |                      |
| Q1 (Men 0.00–7.07; Women 0.00–5.69) | 159   | 76     | 1487.59       | 51.09          | 1.00                 |
| Q2 (Men 7.08–7.58; Women 5.70–6.14) | 160   | 46     | 1667.29       | 27.59          | 0.52 (0.36, 0.75)**   |
| Q3 (Men 7.59–8.05; Women 6.15–6.63) | 161   | 36     | 1733.23       | 20.77          | 0.38 (0.26, 0.57)**   |
| Q4 (Men ≥ 8.06; Women ≥ 6.64)     | 161   | 40     | 1735.44       | 23.05          | 0.43 (0.29, 0.63)**   |
| **Weight-adjusted SMI (%)**       |       |        |               |                |                      |
| Q1 (Men 0.00–28.97; Women 0.00–23.54) | 159   | 67     | 1588.36       | 42.18          | 1.00                 |
| Q2 (Men 28.98–31.31; Women 23.55–25.58) | 161   | 43     | 1661.54       | 25.88          | 0.60 (0.41, 0.88)**   |
| Q3 (Men 31.32–33.61; Women 25.59–27.92) | 163   | 47     | 1703.08       | 27.60          | 0.64 (0.44, 0.94)*    |
| Q4 (Men ≥ 33.62; Women ≥ 27.93)    | 158   | 41     | 1670.57       | 24.54          | 0.57 (0.39, 0.84)**   |
| **Physical performance**          |       |        |               |                |                      |
| Gait speed (m/s)                 |       |        |               |                |                      |
| Q1 (Men 0.00–0.71; Women 0.00–0.68) | 157   | 91     | 1403.52       | 64.84          | 1.00                 |
| Q2 (Men 0.72–0.85; Women 0.69–0.82) | 155   | 43     | 1666.93       | 25.80          | 0.37 (0.25, 0.53)**   |
| Q3 (Men 0.86–0.98; Women 0.83–0.92) | 169   | 36     | 1806.21       | 19.93          | 0.28 (0.19, 0.42)**   |
| Q4 (Men ≥ 0.99; Women ≥ 0.93)     | 160   | 28     | 1746.89       | 16.03          | 0.23 (0.15, 0.35)**   |
| Timed up-and-go test (sec)       |       |        |               |                |                      |
| Q1 (Men 0.00–6.05; Women 0.00–6.49) | 161   | 30     | 1742.89       | 17.21          | 1.00                 |
| Q2 (Men 6.06–6.97; Women 6.50–7.21) | 161   | 33     | 1737.21       | 19.00          | 1.10 (0.67, 1.81)     |
| Q3 (Men 6.98–8.27; Women 7.22–8.67) | 160   | 45     | 1715.24       | 26.24          | 1.53 (0.96, 2.43)     |
| Q4 (Men ≥ 8.28; Women ≥ 8.68)     | 159   | 90     | 1428.21       | 63.02          | 3.97 (2.62, 6.00)**   |
| Timed chair stand (sec)          |       |        |               |                |                      |
| Q1 (Men 0.00–4.18; Women 0.00–4.29) | 162   | 22     | 1810.18       | 12.15          | 1.00                 |
### Table 2 (continued)

| Variables                                      | N   | Deaths | Person- years | Incidence rate | HR (95% CI)          |
|-----------------------------------------------|-----|--------|---------------|----------------|----------------------|
|                                               |     |        |               |                | Crude | Multivariate-adjusted<sup>1</sup> | Multivariate-adjusted<sup>2</sup> |
| Q2 (Men 4.19–4.92; Women 4.30–5.20)           | 160 | 44     | 1689.82       | 26.04          | 2.19 (1.31, 3.66)<sup>**</sup> | 1.82 (1.09, 3.07)<sup>*</sup> | 1.55 (0.92, 2.63) |
| Q3 (Men 4.93–5.89; Women 5.21–6.18)           | 160 | 52     | 1622.43       | 32.05          | 2.74 (1.66, 4.50)<sup>***</sup> | 2.27 (1.37, 3.77)<sup>**</sup> | 2.10 (1.25, 3.51)<sup>**</sup> |
| Q4 (Men ≥ 5.90; Women ≥ 6.19)                 | 159 | 80     | 1501.12       | 53.29          | 4.68 (2.92, 7.50)<sup>***</sup> | 3.14 (1.89, 5.19)<sup>***</sup> | 2.49 (1.48, 4.18)<sup>***</sup> |
|                                               |     |        |               |                | **  | **  | **  |

**Multivariate adjustment** for age, sex, education, marital status, smoking, alcohol drinking, physical activity, and exercising program

**Multivariate adjustment** for age, sex, education, marital status, smoking, alcohol drinking, physical activity, exercising program, hypertension, diabetes mellitus, heart disease, stroke, cancer, cognitive impairment, fasting plasma glucose, triglyceride, high-density lipoprotein, low-density lipoprotein, and estimated glomerular filtration rate

Incidence rate = (number of incident cases) / (1000 person-years); SMM skeletal muscle mass, HR Hazard ratio, CI Confidence interval

<sup>*</sup> <i>p </i> < 0.05; <sup>**</sup> <i>p </i> < 0.01; <sup>***</sup> <i>p </i> < 0.001
muscle loss. This can be supported by the lower overall cumulative mortality or disability (19.67%) in Japan study, compared with ours (30.89%).

In terms of physical performance, several studies have indicated that physical performance measures of GS, TUG, TCS, WaLP, and HS were better than the SMI in older adults for predicting future death [28] and can be used as a clinical screening tool [16–23]. Therefore, the combination of physical performance and SMI is likely to strengthen its association with adverse outcomes. Physical performance measures can be performed with relative ease in a clinical setting when evaluation of the physical function component of sarcopenia is required. Our study demonstrated that the combination of hSMI with physical function improved mortality risk prediction.

Sarcopenia is a complex syndrome that is characterized by progressive and generalized loss of muscle mass and strength or physical performance with an increased risk for mortality [46]. In 2010, the EWGSOP promulgated a sarcopenia definition that has been widely used either in clinical settings or community that advances in scientific research of sarcopenia [2]. This original criteria of diagnosis for sarcopenia is defined as low muscle mass plus low muscle strength or physical performance. Based on the accumulative scientific evidence, 2018 EWGSOP definition used low muscle strength as the primary parameter for defining probable sarcopenia; a confirmed sarcopenia diagnosis is made when probable sarcopenia with the presence of low muscle quantity or quality is detected [2]. When the presence of low muscle strength, low muscle quantity/quality and low physical performance are detected, sarcopenia is considered to be severe. The AWGS 2014 consensus defined sarcopenia similar to the 2010 EWGSOP definition [47]. Its revised definition in 2019 retains the previous definition due to limited data on Asian people [48]. Our study indicated that heighted-adjusted SMI and physical performance (GS, TUG, TCS, WaLP, and HS) are independent mortality predictors of traditional risk factors, consistent with previous studies [10–28, 45, 49]. Our study’s findings support the use of heighted adjusted SMI in AWGS sarcopenia definition because heighted adjusted SMI was the only muscle mass index associated with mortality. In addition, our study’s findings indicate men with handgrip strength lower than 28.69 kg and women lower than 18.79 kg, determined by first quartile, were associated with an increased risk of

![ROC Curves for Comparisons](image)

Fig. 1 The areas under the receiver operating characteristic curves for all-cause mortality. The AUCs for models with additional consideration of TUG and all skeletal muscle mass and physical performance variables were significantly higher than that for model with baseline characteristics (p<0.01)
mortality, which is in accordance with the cutoff point of handgrip strength in AWGS sarcopenia definition (28 kg for men and 18 kg for women).

This present study is a prospective, community-based observational cohort research. Study data were collected using standardized procedures and measurement instruments to ensure the validity and reliability. Death records of study samples were obtained through the linkage of national death dataset of Taiwan Ministry of Health and Welfare and have been regularly assessed for validity. Several limitations should be mentioned when interpreting the results of this study. First, the SMI measured by using DXA may be inaccurate in the calculation of the overall muscle mass throughout the body; however, DXA is a reliable method for use as a reference standard (but not a gold standard) for measuring muscle mass \[50\]. Second, our study covered the noninstitutionalized older adults, omitting residents in the nursing home who have high risks of dementia and death, which may limit the generalization of our study’s findings. The possibility of selection bias may occur during identification of the study population. However, based on the similar distributions of age and gender between our sample and target population, the potential selection bias may be minimized. Our findings can be generalized to older population in Taichung city.

**Conclusion**

The hSMI is a useful indicator in the prediction of long-term mortality in men but not in women. Consistently, physical performance measures of walking speed, TUG, TCS, waLP, and HS are also considered valid or meaningful predictors. Our study suggested that hSMI and physical performance are key indicators, individually or in combination, in the prediction of mortality, which may help target interventions to improve survival among older adults.

**Abbreviations**

SMI: Skeletal muscle index; TUG: Timed up-and-go; EWGSOP: European Working Group on Sarcopenia in Older People; AWGS: Asian Working Group
for Sarcopenia, GS. Gait speed; HRC. Human Research Committee; MMSE: Mini-mental State Examination; DXA. Dual-energy X-ray absorptiometry; HSMI: Height-adjusted skeletal muscle index; wSMI: Weight-adjusted skeletal muscle index; TCS: Timed chair stands; waLP: Weight-adjusted leg press; HS: Handgrip strength; SD: Standard deviation; HR: Hazard ratio; CIs: Confidence interval; AUC: Area under the curve.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12877-022-03292-0.

**Additional file 1: Supplement Figure S1.** The flowchart of recruitment procedures of the current study. **Supplement Figure S2.** Kaplan-Meier curves for all-cause mortality by quartiles of (a) height-adjusted SMI, (b) gait speed, (c) TUG, (d) TCS, (e) WaLP, and (f) handgrip strength.

**Acknowledgements**

This study was supported primarily by the Ministry of Science and Technology of Taiwan (MOST 104-2314-B-039-016, MOST 105-2314-B-039-021-MY3 & MOST 105-2314-B-039-025-MY3 & MOST 107-2314-B-039-049- & MOST 108-2314-B-039-039- & MOST 108-2314-B-039-035-MY3 & MOST 108-2314-B-039-031-MY2 & MOST 109-2314-B-039-021-MY2 & MOST 110-2314-B-039-021-MY2) and by China Medical University Hospital (DMR-110-077).

**Authors’ contributions**

TCL and CCL were responsible for the conception and design of the study. CIL and SYI acquired data and analysed data. CIL and CHL interpreted data. TCL and CCL were responsible for the integrity of the work as a whole. The author(s) read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

The datasets generated and/or analyzed during the current study are not publicly available due to the policy declared by National Health Insurance in Taiwan but are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

This present study was approved by the Ethical Review Board of China Medical University Hospital (DMR 97-IRB-055 & CMUH108-REC2-161). Written informed consent was obtained from all the study participants. All methods were performed in accordance with the relevant guidelines and regulations.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. 2 Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. 3 Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan. 4 Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan. 5 Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan.

**Received:** 30 September 2021 **Accepted:** 12 July 2022 **Published online:** 18 July 2022

**References**

1. Kajimura M. Changes in the Demographic Structure and Economic Growth in East and Southeast Asia. 2020.
2. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin F, Michel JP, Rolland Y, Schneider SM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23.
3. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuilhe D, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition, prevalence, etiology, and consequences. International Working Group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–56.
4. Gale CR, Martyn CN, Cooper C, Sayer AA. Grip strength, body composition, and mortality. Int J Epidemiol. 2007;36(1):228–35.
5. Janssen I, Heysmfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50(5):891–4.
6. Landi F, Liperoti R, Fusco D, Mastroppoalo S, Quattrociocchi D, Proia A, Tosato M, Bernabei R, Onder G. Sarcopenia and mortality among older nursing home residents. J Am Med Dir Assoc. 2012;13(2):121–6.
7. Sayer AA, Dennison EM, Syddall HE, Gilbody HJ, Phillips DI, Cooper C. Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg? Diabetes Care. 2005;28(10):2541–5.
8. Visser M, Goodpaster BH, Kritchevsky SB, Newman AB, Nevitt M, Rubin SM, Simonsick EM, Harris TB. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci. 2005;60(3):324–33.
9. Argiles JM, Campos N, Lopez-Pedrosa JM, Rueda R, Rodriguez-Manas L. Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease. J Am Med Dir Assoc. 2016;17(9):789–95.
10. Wang H, Hai S, Liu Y, Liu Y, Dong B. Skeletal Muscle Mass as a Mortality Predictor among Nonagenarians and Centenarians: A Prospective Cohort Study. Sci Rep. 2019;9(1):2420.
11. Chuang SY, Chang HY, Lee MS, Chi-Yu Chen R, Pan WH. Skeletal muscle mass and risk of death in an elderly population. Nutr Metab Cardiovasc Dis. 2014;24(7):784–91.
12. Chuang SY, Hsu YY, Chen RC, Liu WL, Pan WH. Abdominal Obesity and Low Skeletal Muscle Mass Jointly Predict Total Mortality and Cardiovascular Mortality in an Elderly Asian Population. J Gerontol A Biol Sci Med Sci. 2016;71(8):1049–55.
13. Otsuka R, Matsu Y, Tange C, Nishita Y, Tomida M, Ando F, Shimokata H, Arai H. What is the best adjustment of appendicular lean mass for predicting disability or mortality among Japanese community dwellers? BMC Geriatr. 2018;18(1):8.
14. Perkisas S, De Cock AM, Vandewoude M, Verhoeven V. Prevalence of sarcopenia and 9-year mortality in nursing home residents. Aging Clin Exp Res. 2019;31(7):951–9.
15. Srikantan P, Kralamangla AS. Muscle mass index as a predictor of longevity in older adults. Am J Med. 2014;127(6):547–53.
16. Otsuka H, Kobayashi H, Suzuki K, Hayashi Y, Ikeda J, Kushimoto M, Hara M, Abe M, Kato K, Soma M. Mobility performance impacts mortality risk in community-dwelling healthy older adults in Japan: a prospective observational study. Aging Clin Exp Res. 2021;33(9):2511–7.
17. Eekhoff EMW, van Schoor NM, Bierma-Zeinstra SM, Oosterwerff MM, de Jongh R, Bravenboer N, van Poppel MM, Deeg DJH. Relative importance of four functional measures as predictors of 15-year mortality in the older Dutch population. BMC Geriatr. 2019;19(1):92.
18. Idland G, Engedal K, Bergland A. Physical performance and 13.5-year mortality in elderly women. Scand J Public Health. 2013;41(1):102–8.
19. Chen PJ, Lin MH, Peng LN, Liu CL, Chang CW, Lin YT, Chen LK. Predicting cause-specific mortality of older men living in the Veterans home by handgrip strength and walking speed: a 3-year, prospective cohort study in Taiwan. J Am Med Dir Assoc. 2012;13(6):517–21.
20. Takata Y, Shimada M, Anshi T, Yoshitake Y, Nishimuta M, Nakagawa N, Ohashi M, Yoshiihra A, Miyazaki H. Physical performance and 10-year mortality in a 70-year-old community-dwelling population. Aging Clin Exp Res. 2012;24(3):257–64.
21. Veronese N, Stubbs B, Fontana L, Trevisan C, Rolzetta F, Rui M, Sartori L, Musacchio E, Zambon S, Maggi S, et al. A Comparison of Objective
Physical Performance Tests and Future Mortality in the Elderly People. J Gerontol A Biol Sci Med Sci. 2017;72(3):362–8.

22. Cesari M, Kritchevsky SB, Newman AB, Simonsick EM, Harris TB, Penninx BW, Brach JS, Tylavsky FA, Satterfield S, Bauer DC, et al. Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging And Body Composition Study. J Am Geriatr Soc. 2009;57(2):251–9.

23. De Buyster SL, Petrovic M, Taes YE, Toye KR, Kaufman JM, Goemaere S. Physical function measurements predict mortality in ambulatory older men. Eur J Clin Invest. 2013;43(4):379–86.

24. Bjorckman MP, Ptkala KH, Jyvakorpi S, Strandberg TE, Tilvis RS. Biompedance analysis and physical functioning as mortality indicators among older sarcopenic people. Exp Gerontol. 2019;122:42–6.

25. Cheung CL, Lam KS, Cheung BM. Evaluation of Cutpoints for Low Lean Mass and Slow Gait Speed in Predicting Death in the National Health and Nutrition Examination Survey 1999–2004. J Gerontol A Biol Sci Med Sci. 2016;71(1):90–5.

26. Li R, Xia J, Zhang XJ, Gathina-Mwangi WG, Guo J, Li Y, Mckenzie S, Song Y. Associations of Muscle Mass and Strength with All-Cause Mortality among US Older Adults. Med Sci Sports Exerc. 2018;50(3):458–67.

27. Sim M, Prince RL, Scott D, Daly RM, Duque G, Inderjeeth CA, Zhu K, Woodman RJ, Hodgson JM, Lewis JR. Sarcopenia Definitions and Their Associations With Mortality in Older Australian Women. J Am Med Dir Assoc. 2019;20(1):76–82.e72.

28. Kim YH, Kim KI, Paik NJ, Kim KW, Jang HC, Lim JY. Muscle strength: A better index of low physical performance than muscle mass in older adults. Geriatr Gerontol Int. 2016;16(5):577–85.

29. Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, Tylavsky FA, Rubin SM, Harris TB. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J Gerontol A Biol Sci Med Sci. 2006;61(1):72–7.

30. Meng NH, Li CI, Liu CS, Lin WY, Lin CH, Chang CK, Li TC, Lin CC. Sarcopenia Defined by Combining Height- and Weight-Adjusted Skeletal Muscle Indices is Closely Associated With Poor Physical Performance. J Aging Phys Act. 2015;23(4):597–606.

31. Neves T, Fett CA, Ferrioli E, Crespiho Souza MG, Dos Reis Filho AD, Martin Lopes MB, Caiaro Martins NM, Rezende Fett WC. Correlation between muscle mass, nutritional status and physical performance of elderly people. Osteoporosis and sarcopenia. 2018;4(4):145–9.

32. Chang JS, Kim TH, Kim H, Choi EH, Kim N, Kong ID. Qualitative muscle mass index as a predictor of skeletal muscle function deficit in Asian older adults. Geriatr Gerontol Int. 2017;17(1):99–107.

33. Knowles R, Carter J, Jebb SA, Bennett D, Lewington S, Bierras C. Associations of Skeletal Muscle Mass and Fat Mass With Incident Cardiovascular Disease and All-Cause Mortality: A Prospective Study of UK Biobank Participants. J Am Heart Assoc. 2021;10(9):e019337.

34. Lee DH, Keum N, Hu FB, Orav EJ, Rimm EB, Willett WC, Giovannucci EL. Predicted lean body mass, fat mass, and all cause and cause specific mortality in men: prospective US cohort study. BMJ (Clinical research ed). 2018;362:k2575.

35. Chua KY, Lim WS, Lin X, Yuan JM, Koh WP. Handgrip Strength and Timed Up-and-Go (TUG) Test are Predictors of Short-Term Mortality among Elderly in a Population-Based Cohort in Singapore. J Nutr Health Aging. 2020;24(4):371–8.

36. Meng NH, Li CI, Liu CS, Lin CH, Chang CK, Chang HW, Yang CW, Li TC, Lin CC. Effects of concurrent aerobic and resistance exercise in frail and pre-frail older adults: A randomized trial of supervised versus home-based programs. Medicine. 2020;99(29):e21187.

37. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.

38. Wang MC, Li TC, Li CI, Liu CS, Brach JS, Tylavsky FA, Satterfield S, Bauer DC, et al. Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging And Body Composition Study. J Am Geriatr Soc. 2004;52(8):1343–8.

39. Chua KY, Liao JM, Fong P, Kong ID. Comparison of clinical and biomolecular measures of balance and mobility in elderly nursing home residents. J Am Geriatr Soc. 1994;42(3):493–500.

40. Brazycki M. Strength testing—predicting a one-rep max from reps-to-fatigue. J Phys Educ Recreat Dance. 1993;64(1):88-90.

41. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics. 1988;44(3):837–45.

42. de Santana FM, Premao MR, Tanigawa NY, Pereira RMR. Low muscle mass in older adults and mortality: A systematic review and meta-analysis. Exp Gerontol. 2021;152:111461.

43. Miyake H, Kanazawa I. Low skeletal muscle mass is associated with the risk of all-cause mortality in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2019;10:20218819842971.

44. Dhillon RJ, Hasn S. Pathogenesis and Management of Sarcopenia. Clin Geriatr Med. 2017;33(1):17–26.

45. Chen LK, Liu MK, Song Y, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krishna G, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014;15(2):95–101.

46. Chen LK, Wou J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21(3):300-307.e302.

47. Reijnierse EM, Verlaan S, Pham VK, Lim WK, Meskers CGM, Maier AB. Lower skeletal muscle mass at admission independently predicts falls and mortality three months post-discharge in hospitalised older patients. J Gerontol A Biol Sci Med Sci. 2019;74(10):1650-6.

48. Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, Maggi S, Dennison E, Al-Daghri NM, Allepaerts S, et al. Pitfalls in the measurement of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Muscle. 2018;9(2):269–78. 

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more: biomedcentral.com/submissions